When was Corline Biomedical founded?

Corline Biomedical was founded in 1991 and raised its 1st funding round 20 years after it was founded.

Where is Corline Biomedical located?

Corline Biomedical is headquartered in Uppsala, Sweden.

Who is the current CEO of Corline Biomedical?

Henrik Nittmar of Corline Biomedical.

Is Corline Biomedical a funded company?

Corline Biomedical is a funded company, having raised an undisclosed amount across 6 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jun 07, 2011.

When was the latest funding round of Corline Biomedical?

Corline Biomedical's latest funding was a $***** Post IPO round on Mar 29, 2021, with participation from 2 investors.

Where does Corline Biomedical rank among its competitors?

Corline Biomedical ranks 18th amongst 109 active competitors, of which 36 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Enyo Pharma, which secured $6.87M in Jun, 2025.

Who are the top competitors of Corline Biomedical?

Corline Biomedical's top competitors include Calliditas Therapeutics, Enyo Pharma and Arthrosi Therapeutics. Among them, Enyo Pharma secured the most recent funding round in June, 2025.

Corline Biomedical - 2026 Company Profile, Team, Funding & Competitors

Corline Biomedical is a public company based in Uppsala (Sweden), founded in 1991. It operates as a Developing solutions for transplantation, implants and regenerative medicine using a proprietary heparin platform. Corline Biomedical has raised an undisclosed amount in funding. The company has 109 active competitors, including 36 funded and 28 that have exited. Its top competitors include companies like Calliditas Therapeutics, Enyo Pharma and Arthrosi Therapeutics.

Company Details

Corline Biomedical is a public company that develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. The company's products are based on its proprietary Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as a stand-alone pharmaceutical compound; and Corline Heparin Surface (CHS), a surface coating that is used in conventional medical devices for blood compatibility. The company’s products include Renaparin for use in the treatment of end-stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; and CHC, which is used for the treatment of soft tissue injuries. It also provides heparin coating kits, which allows the customers to coat one-off items and equipment in a lab setting; and CHS coronary stents, a metallic tube-shaped device, which is placed in the coronary arteries that supplies blood to the heart, for the treatment of acute or threatened vessel closure during coronary angioplasty.

Website: www.corline.se/
Email ID: *****@corline.se

Key Metrics

Founded Year

1991

Location

Uppsala, Sweden

Stage

Public

Latest Funding Round

Post IPO, Mar 29, 2021, $*****

Investors

M2 Asset Management AB & 3 more

Ranked

18^th among 109 active competitors

Similar Companies

Calliditas Therapeutics & 122 more

Exit Details

Public

View Corline Biomedical's full profile

Corline Biomedical got listed on Jun 05, 2015.

Click here to take a look at Corline Biomedical's IPO in detail

Corline Biomedical has raised funding over 6 rounds. Its first funding round was on Jun 07, 2011. Its latest funding round was a Post IPO round on Mar 29, 2021 for $*****. 2 investors participated in its latest round. Corline Biomedical has 4 institutional investors.

Here is the list of recent funding rounds of Corline Biomedical:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 29, 2021	2928158	Post IPO	6859548	4960734	7606814	6694154
Feb 28, 2019	5208351	Grant (prize money)	4181831	9254866	3889431	EIC Fund
Mar 01, 2017	3408108	Grant (prize money)	3688724	2660930	4974835	Europa

Access funding benchmarks and valuations. Sign up today!

View details of Corline Biomedical's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Corline Biomedical include Calliditas Therapeutics, Enyo Pharma and Arthrosi Therapeutics. Here is the list of Top 10 competitors of Corline Biomedical, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Calliditas Therapeutics 2004, Stockholm (Sweden), Public	Provider of small molecule based drug for inflammatory kidney disease	$44.8M	Investinor, Athyrium Capital Management & 3 others	62/100
2nd	Enyo Pharma 2014, Lyon (France), Series C	Developer of therapeutics for diseases with impaired kidney function	$120M	Orbimed, Morningside & 9 others	62/100
3rd	Arthrosi Therapeutics 2017, Irvine (United States), Acquired	Developer of therapeutics for gout, chronic kidney diseases, and oncology	$293M	Prime Eight Capital, Guangrun Health Industry ... & 11 others	62/100
4th	Renalys 2023, Chuo City (Japan), Acquired	Developer of therapeutics for the treatment of renal diseases	$38.2M	SR One, Catalys Pacific & 4 others	61/100
5th	Alebund 2018, Shanghai (China), Series B	Developer of therapeutics for kidney diseases	$114M	Morningside, Quan Capital & 14 others	58/100
6th	Aurinia Pharmaceuticals 1993, Edmonton (Canada), Public	Developer of therapeutics for autoimmune diseases	-	RA Capital Management, Redmile Group & 10 others	58/100
7th	Unicycive 2016, San Francisco (United States), Public	Developer of small molecule therapies for the treatment of kidney diseases	$1.55M	Logos, Vivo Capital & 5 others	57/100
8th	Purespring Therapeutics 2020, London (United Kingdom), Series B	Developer of therapeutics for chronic renal diseases	$164M	Syncona, Sofinnova Partners & 3 others	57/100
9th	Secretome Therapeutics 2018, Dallas (United States), Series B	Developer of cell-based therapies for multiple diseases	$21.9M	USM, Maryland Momentum Fund	57/100
10th	Renibus Therapeutics 2013, Southlake (United States), Series B	Provider of therapeutics to treat kidney diseases	$169M	Oxford Finance, AG Collective Capital & 1 others	55/100
18th	Corline Biomedical 1991, Uppsala (Sweden), Public	Developing solutions for transplantation, implants and regenerative medicine using a proprietary heparin platform	-	M2 Asset Management AB, EIC Fund & 2 others	50/100